Your browser doesn't support javascript.
loading
The Q359K/T360K mutation causes cystic fibrosis in Georgian Jews.
Mei-Zahav, M; Stafler, P; Senderowitz, H; Bentur, L; Livnat, G; Shteinberg, M; Orenstein, N; Bazak, L; Prais, D; Levine, H; Gur, M; Khazanov, N; Simhaev, L; Eliyahu, H; Cohen, M; Wilschanski, M; Blau, H; Mussaffi, H.
Afiliación
  • Mei-Zahav M; Kathy and Lee Graub Cystic Fibrosis Center and Pulmonary Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: mmeizahav@gmail.com.
  • Stafler P; Kathy and Lee Graub Cystic Fibrosis Center and Pulmonary Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Senderowitz H; Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel.
  • Bentur L; Pediatric Pulmonary Institute, Ruth Rappaport Children's Hospital, Rambam health Care Campus, Israel; Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel.
  • Livnat G; Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel; Cystic Fibrosis Center, Carmel Hospital, Israel.
  • Shteinberg M; Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel; Cystic Fibrosis Center, Carmel Hospital, Israel.
  • Orenstein N; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Raphael Recanati Genetics Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
  • Bazak L; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Raphael Recanati Genetics Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
  • Prais D; Kathy and Lee Graub Cystic Fibrosis Center and Pulmonary Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Levine H; Kathy and Lee Graub Cystic Fibrosis Center and Pulmonary Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Gur M; Pediatric Pulmonary Institute, Ruth Rappaport Children's Hospital, Rambam health Care Campus, Israel.
  • Khazanov N; Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel.
  • Simhaev L; Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel.
  • Eliyahu H; Electrophysiology Laboratory, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Cohen M; Electrophysiology Laboratory, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Wilschanski M; Electrophysiology Laboratory, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Blau H; Kathy and Lee Graub Cystic Fibrosis Center and Pulmonary Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Mussaffi H; Kathy and Lee Graub Cystic Fibrosis Center and Pulmonary Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Cyst Fibros ; 17(5): e41-e45, 2018 09.
Article en En | MEDLINE | ID: mdl-30033373
BACKGROUND: The Q359K/T360K mutation, described in Jewish CF patients of Georgian decent, is of questionable clinical significance. METHODS: Clinical records of patients with the Q359K/T360K mutation from three CF centers were studied for phenotypic expression and putative mechanism of dysfunction. Computer models of mutant CFTR were constructed. RESULTS: Nine patients (4 homozygous) of Georgian Jewish origin were included. Age at diagnosis was 9.4 (0.25-38.2) years, median (range). Sweat chloride was 106 ±â€¯13 meq/L, mean ±â€¯SD. Nasal Potential Difference performed in three, was abnormal. All had pulmonary symptoms since early childhood and bronchiectasis. Median FEV1 was 88 (40-121)%. Five had chronic mucoid P. aeruginosa. Homozygous patients were pancreatic insufficient. Enzyme supplementation was initiated at 3.8 (1-14.7) years, median (range). Structural models hint at possible interference of this mutation with transmembrane chloride transport. CONCLUSION: In our cohort, the Q359K/T360K mutation resulted in a severe CF phenotype, although with residual early CFTR function. The CFTR2 database should consider defining this mutation as CF-causing.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Judíos / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Fibrosis Quística Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: J Cyst Fibros Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Judíos / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Fibrosis Quística Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: J Cyst Fibros Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos